Adverse event cases after Covid-19 vaccination just one in 2,000: Govt

Dispelling rumours, NITI Aayog member (Health) V K Paul said the vaccination will not impact fertility in any manner

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Representational image
Press Trust of India New Delhi
1 min read Last Updated : Feb 16 2021 | 9:01 PM IST
Just one out of 2,000 beneficiaries report minor effects post vaccination against COVID-19, the Centre on Tuesday said, noting that the rate of adverse event following immunisation has been recorded at 0.05 per cent.

Dispelling rumours, NITI Aayog member (Health) V K Paul said the vaccination will not impact fertility in any manner.

"The AEFI is 0.05 per cent, it is 1 in 2000 there is slight pain or fever. Spreading rumours like it will impact fertility are not true. The vaccines are eminently safe. I will appeal anganwadi workers and nurses to get vaccinated," he said.

ICMR Director General Balram Bhargava further added that those taking aspirin and blood thinner can also be given these vaccines.

"There is no contraindication," he said.

Paul further said 24 countries have been sent vaccinations from India.

He urged people to maintain vigil and keep following COVID appropriate behaviour.

"70 per cent Indian population is still vulnerable. Vigil to contain this virus must continue. We still don't fully understand the virus so we have to be serious about vaccination and COVID-19's appropriate behaviour," he said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story